ATE245641T1 - Antivirale pyrimidinderivate - Google Patents

Antivirale pyrimidinderivate

Info

Publication number
ATE245641T1
ATE245641T1 AT99905966T AT99905966T ATE245641T1 AT E245641 T1 ATE245641 T1 AT E245641T1 AT 99905966 T AT99905966 T AT 99905966T AT 99905966 T AT99905966 T AT 99905966T AT E245641 T1 ATE245641 T1 AT E245641T1
Authority
AT
Austria
Prior art keywords
pyrimidine derivatives
antiviral pyrimidine
antiviral
compounds
compositions
Prior art date
Application number
AT99905966T
Other languages
English (en)
Inventor
Timothy D Cushing
Heather L Mellon
Juan C Jaen
John A Flygare
Shi-Chang Miao
Xiaoqi Chen
Jay P Powers
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Application granted granted Critical
Publication of ATE245641T1 publication Critical patent/ATE245641T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99905966T 1998-02-17 1999-02-12 Antivirale pyrimidinderivate ATE245641T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7500598P 1998-02-17 1998-02-17
PCT/US1999/003136 WO1999041253A1 (en) 1998-02-17 1999-02-12 Anti-viral pyrimidine derivatives

Publications (1)

Publication Number Publication Date
ATE245641T1 true ATE245641T1 (de) 2003-08-15

Family

ID=22122948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905966T ATE245641T1 (de) 1998-02-17 1999-02-12 Antivirale pyrimidinderivate

Country Status (14)

Country Link
US (3) US6200977B1 (de)
EP (1) EP1056742B1 (de)
JP (1) JP2002503662A (de)
KR (1) KR20010041015A (de)
CN (1) CN1297447A (de)
AT (1) ATE245641T1 (de)
AU (1) AU748087B2 (de)
BR (1) BR9908004A (de)
CA (1) CA2321153A1 (de)
DE (1) DE69909756D1 (de)
EA (1) EA200000840A1 (de)
IL (1) IL137922A0 (de)
NZ (1) NZ506417A (de)
WO (1) WO1999041253A1 (de)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200000840A1 (ru) * 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
SK287270B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
SI1129079T1 (sl) * 1998-11-10 2006-06-30 Janssen Pharmaceutica Nv 2,4-disubstituirani triazinski derivati z anti-HIV aktivnostjo
EP1206260A4 (de) 1999-06-30 2002-10-30 Merck & Co Inc Src-kinase hemmende verbindungen
EP1194152A4 (de) * 1999-06-30 2002-11-06 Merck & Co Inc Verbindungen zur SRC Kinase-Hemmung
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
US6410726B1 (en) 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
AU3704101A (en) * 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002039958A2 (en) * 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20040127502A1 (en) 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
AU2002258400A1 (en) * 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US6958340B2 (en) * 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
EA007165B1 (ru) * 2001-09-21 2006-08-25 Санофи-Авентис Производные замещенного 2-пиримидинил-6, 7, 8, 9-тетрагидропиримидо [1,2-а]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1, 2-а]пиримидин-5( 1н )она для нейродегенеративных нарушений
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
KR100516434B1 (ko) * 2002-04-04 2005-09-22 (주) 비엔씨바이오팜 6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EP1518855B1 (de) * 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidincarbonsäureamidderivat
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
EP1389461A1 (de) * 2002-08-14 2004-02-18 Axxima Pharmaceuticals Aktiengesellschaft Pyrimidone mit antiviralen Eigenschaften
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004018435A1 (en) 2002-08-24 2004-03-04 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
DE10251914A1 (de) * 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
DE10305785A1 (de) 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
US7550480B2 (en) * 2003-02-14 2009-06-23 Smithkline Beecham Corporation Compounds
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
KR100502395B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 4-[4-(4-모르포리노)아닐리노]피리미딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물.
KR100502394B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 2-[2-(4-모르포리노)에틸아미노]피리딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
AU2004295050A1 (en) 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
US7592340B2 (en) * 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
TWI355894B (en) 2003-12-19 2012-01-11 Du Pont Herbicidal pyrimidines
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
EP2543376A1 (de) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazin Kinasehemmer
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
JP2007537230A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の処置用のピリミジン誘導体
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
EP2311827A1 (de) 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidin-Derivat zur Verwendung als Zwischenprodukt Chemokine-Rezeptor-Modulatoren
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
CN101084214A (zh) * 2004-11-17 2007-12-05 迈卡纳治疗股份有限公司 激酶抑制剂
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
MX2007007272A (es) * 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
US7187123B2 (en) * 2004-12-29 2007-03-06 Dupont Displays, Inc. Display device
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
BRPI0606793A8 (pt) 2005-02-04 2018-03-13 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US7423042B2 (en) * 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
EP1883302A4 (de) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc Jak-kinase-hemmer und deren verwendung
DK1877384T3 (da) * 2005-05-06 2011-08-15 Du Pont Fremgangsmåde til fremstilling af eventuelt 2-substituerede 1,6-dihydro-6-oxo-4-pyrimidincarboxylsyrer
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
DE602006013970D1 (de) * 2005-05-16 2010-06-10 Du Pont Verfahren zur herstellung substituierter pyrimidine
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
JP4278172B2 (ja) * 2005-07-30 2009-06-10 アストラゼネカ アクチボラグ 増殖性疾患の治療において使用するためのイミダゾリル−ピリミジン化合物
ATE542814T1 (de) * 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
AR056556A1 (es) 2005-09-30 2007-10-10 Astrazeneca Ab Imidazo(1,2-a)piridina con actividad antiproliferacion celular
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
MX2008005814A (es) * 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
PL2007752T3 (pl) 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
EP2043651A2 (de) * 2006-07-05 2009-04-08 Exelixis, Inc. Verfahren zur verwendung von igf1r und abl-kinase-modulatoren
CA2668429A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
ES2347721T3 (es) * 2006-12-19 2010-11-03 Vertex Pharmaceuticals, Inc. Aminopirimidinas utiles como inhibidores de proteina quinasas.
EP2133095A4 (de) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd Pharmazeutische zusammensetzung
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AU2008226457B2 (en) * 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
EP2137183B1 (de) * 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EP2134709A1 (de) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridine als proteinkinasehemmer
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CA2694381A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
MX2009011811A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2164842A2 (de) * 2007-05-24 2010-03-24 Vertex Pharmaceuticals Incorporated Als kinaseinhibitoren geeignete thiazole und pyrazole
EP2166849A4 (de) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc Substituierte pyrazol-verbindungen
NZ582879A (en) * 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
DE102007061756A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TWI498326B (zh) 2008-06-30 2015-09-01 Janssen Pharmaceutica Nv 用於製備經取代之嘧啶衍生物之化合物
US20100029942A1 (en) 2008-06-30 2010-02-04 Sergio Cesco-Cancian Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2344470B1 (de) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexylderivate als modulatoren von metabotropen glutamatrezeptoren
MX2011002312A (es) * 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
KR20110063447A (ko) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
US20120077813A1 (en) * 2009-04-15 2012-03-29 Astrazeneca Ab Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
PT3012258T (pt) 2010-06-24 2018-12-14 Gilead Sciences Inc Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral
EP2603511B1 (de) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-on derivate und ihre verwendung als pde9a inhibitoren
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
PT3590928T (pt) 2011-04-08 2021-08-19 Janssen Sciences Ireland Unlimited Co Derivados de pirimidina para o tratamento de infeções virais
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
AU2013221286B2 (en) * 2012-02-17 2017-06-15 Abbvie Inc. Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (RSV)
WO2013146963A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
AU2013249280B2 (en) 2012-04-17 2017-10-12 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
EA035790B1 (ru) 2012-07-13 2020-08-11 Янссен Сайенсиз Айрлэнд Юси Макроциклические пурины для лечения вирусных инфекций
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
EA035431B1 (ru) 2012-11-16 2020-06-15 Янссен Сайенсиз Айрлэнд Юси Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
SG11201506639XA (en) 2013-02-21 2015-09-29 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
SMT202000084T1 (it) 2013-03-06 2020-03-13 Janssen Pharmaceutica Nv Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina
CN110590809B (zh) 2013-03-29 2022-04-19 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
SG11201509520QA (en) 2013-05-24 2015-12-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
PT3030563T (pt) 2013-06-27 2017-11-15 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
DK3027624T3 (en) 2013-07-30 2019-01-07 Janssen Sciences Ireland Uc THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
JP6626981B2 (ja) * 2016-01-29 2019-12-25 サムジン ファーマシューティカル カンパニー，リミテッド Ｊｎｋ阻害活性を有する新規なイミダゾール誘導体およびその用途
MA45539A (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
ES2912945T3 (es) 2016-09-29 2022-05-30 Janssen Sciences Ireland Unlimited Co Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE143615C (de)
CH376115A (de) 1957-12-06 1964-03-31 Ciba Geigy Verfahren zur Herstellung neuer substituierter Pyrimidine
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4788195A (en) 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
US5364865A (en) * 1992-12-30 1994-11-15 Sterling Winthrop Inc. Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
TW252112B (de) * 1993-08-19 1995-07-21 Pfizer
DK0640599T3 (da) * 1993-08-26 1998-09-28 Ono Pharmaceutical Co 4-Aminopyrimidin-derivater
DE4408404A1 (de) 1994-03-12 1995-09-14 Huels Chemische Werke Ag Verfahren zur Herstellung von Chlorpyrimidinen
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
KR100239800B1 (ko) 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
EA200000840A1 (ru) * 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина

Also Published As

Publication number Publication date
US6835726B2 (en) 2004-12-28
AU748087B2 (en) 2002-05-30
IL137922A0 (en) 2001-10-31
KR20010041015A (ko) 2001-05-15
US6528513B2 (en) 2003-03-04
US6200977B1 (en) 2001-03-13
CN1297447A (zh) 2001-05-30
BR9908004A (pt) 2001-12-18
EP1056742B1 (de) 2003-07-23
EP1056742A1 (de) 2000-12-06
EA200000840A1 (ru) 2001-02-26
JP2002503662A (ja) 2002-02-05
AU2599999A (en) 1999-08-30
US20010018436A1 (en) 2001-08-30
US20040006068A1 (en) 2004-01-08
WO1999041253A1 (en) 1999-08-19
CA2321153A1 (en) 1999-08-19
DE69909756D1 (de) 2003-08-28
NZ506417A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
DE69909756D1 (de) Antivirale pyrimidinderivate
ATE295355T1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
ATE254132T1 (de) Antivirale pyrimidin nucleoside derivate
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
WO2002062290A3 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
WO2003053344A3 (en) Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE229945T1 (de) Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
MY128458A (en) Antiviral azaindole derivatives
DK1265889T3 (da) Lægemidler imod virussygdomme
DE69818094D1 (de) Antivirale verbindungen
SE0102315D0 (sv) Compounds
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
DE60121461D1 (de) Kondensierte pyridoindolderivate
DK1037650T3 (da) Præparater til behandling af Staphylococcus aureus-infektioner
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
NZ308398A (en) 2-amino benzoxazin-4-one derivatives and medicaments
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
MXPA05010802A (es) Compuestos heterociclicos para el uso en el tratamiento de infecciones virales.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties